• muscular invasive bladder cancer (MIBC)
• MIBC - (neo)adjuvant (NA)
• MIBC - NA - all population 2
• MIBC - NA - PDL1 positive 1

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• nivolumab based treatment
• nivolumab alone

• versus all
• vs non active control
• vs no additional treatment
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs no additional treatment; 
Risk of bias:  low;   some concerns;   high;  NA;